{"id":234,"date":"2020-04-29T12:46:43","date_gmt":"2020-04-29T07:16:43","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19\/?page_id=234"},"modified":"2020-05-24T21:52:41","modified_gmt":"2020-05-24T16:22:41","slug":"in-the-news","status":"publish","type":"page","link":"https:\/\/nclinnovations.org\/covid19\/in-the-news\/","title":{"rendered":"In the News"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\"><strong>Media coverage of the activities and outputs of TFORD:<\/strong><\/p>\n<ul class=\"\">\n<li><strong>(24 May 2020) &nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/05\/TFORD_News_20200524.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Slide Deck compiling Media Coverage of the work of TFORD to date<\/a>&nbsp; NEW!!<\/strong><\/li>\n<li>(17 May 2020, Pune Times, Times of India) Remdesivir vs Favipiravir &amp; other repurpose drugs for COVID-19: <a href=\"https:\/\/timesofindia.indiatimes.com\/city\/pune\/remdesivir-vs-favipiravir-other-repurpose-drugs-for-covid-19\/articleshow\/75783016.cms\" target=\"_blank\" rel=\"noopener noreferrer\">Link<\/a><\/li>\n<li>(14 May 2020, ToI) Bengal government recommends rheumatoid arthritis drug to fight COVID19: <a href=\"http:\/\/timesofindia.indiatimes.com\/articleshow\/75726661.cms\" target=\"_blank\" rel=\"noopener noreferrer\">Link<\/a><\/li>\n<li>(11 May 2020, CNBC TV18): &nbsp; Expect to complete development of Favipiravir in few weeks, says Laurus Labs: <a href=\"https:\/\/www.cnbctv18.com\/healthcare\/expect-to-complete-development-of-favipiravir-in-few-weeks-says-laurus-labs-5836571.htm\" target=\"_blank\" rel=\"noopener noreferrer\">Link<\/a><\/li>\n<li>(1 May 2020, News18) As Race Hots Up to Find Coronavirus Cure, A Look at Potential Treatments Being Tested for the Pandemic: <a href=\"https:\/\/www.news18.com\/news\/india\/remdesivir-race-hots-up-to-find-coronavirus-cure-a-look-at-potential-treatments-for-the-pandemic-2600457.html\" target=\"_blank\" rel=\"noopener noreferrer\">Link<\/a><\/li>\n<li>(30 April 2020, ToI) Favipiravir &amp; Tocilizumab hold most potential in Covid-1 9: <a href=\"http:\/\/timesofindia.indiatimes.com\/articleshow\/75438783.cms\" target=\"_blank\" rel=\"noopener noreferrer\">Link<\/a><\/li>\n<li>(29 April 2020, ET) Strides develops Favipiravir antiviral tablets; drug shows positive outcome in COVID-19 treatment: <a href=\"https:\/\/health.economictimes.indiatimes.com\/news\/pharma\/strides-develops-favipiravir-antiviral-tablets-drug-shows-positive-outcome-in-covid-19-treatment\/75448928\" target=\"_blank\" rel=\"noopener noreferrer\">Link<\/a><\/li>\n<li>(28 April 2020, BioVoice) Mapping potential drugs for COVID-19: Task Force constituted by PSA releases its assessment: <a href=\"https:\/\/www.biovoicenews.com\/mapping-potential-drugs-for-covid-19-task-force-constituted-by-psa-releases-its-assessment\/\" target=\"_blank\" rel=\"noopener noreferrer\">Link<\/a>&nbsp;<\/li>\n<li>(27 April 2020, News18.com and several other news channels in English and regional languages) Govt Task Force Ranks Favipiravir, Tocilizumab as Most Promising Drugs Against Covid-19: <a href=\"https:\/\/www.news18.com\/news\/india\/coronavirus-treatment-update-covid-19-cure-medicines-favipiravir-tocilizumab-hydroxchloroquine-2595057.html\" target=\"_blank\" rel=\"noopener noreferrer\">Link<\/a>&nbsp;\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul class=\"\">\n<li>News18\/Hindi: <a href=\"https:\/\/hindi.news18.com\/news\/knowledge\/indian-govt-task-force-ranks-favipiravir-tocilizumab-as-most-promising-drugs-against-covid-19-knowat-3065251.html\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/hindi.news18.com\/news\/knowledge\/indian-govt-task-force-ranks-favipiravir-tocilizumab-as-most-promising-drugs-against-covid-19-knowat-3065251.html<\/a><\/li>\n<li>CNBC-TV18: <a href=\"https:\/\/www.cnbctv18.com\/healthcare\/coronavirus-cure-govt-task-force-ranks-favipiravir-tocilizumab-as-promising-drugs-against-covid-19-5805311.htm\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.cnbctv18.com\/healthcare\/coronavirus-cure-govt-task-force-ranks-favipiravir-tocilizumab-as-promising-drugs-against-covid-19-5805311.htm<\/a><\/li>\n<li>Yahoo News: <a href=\"https:\/\/in.news.yahoo.com\/govt-task-force-ranks-favipiravir-153340860.html\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/in.news.yahoo.com\/govt-task-force-ranks-favipiravir-153340860.html<\/a><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<li>(27 April 2020, TFORD Press Release) Mapping Potential Drugs for COVID-19: Task Force for Repurposing of Drugs releases its assessment: <a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/04\/TFORD-PR-20200427.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">PDF<\/a><\/li>\n<li>(19 April 2020, Economic Times) Can coronavirus crisis change Indian science for good?: <a href=\"https:\/\/economictimes.indiatimes.com\/news\/science\/can-coronavirus-crisis-change-indian-science-for-good\/articleshow\/75224904.cms\" target=\"_blank\" rel=\"noopener noreferrer\">Link<\/a><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Media coverage of the activities and outputs of TFORD: (24 May 2020) &nbsp;Slide Deck compiling Media Coverage of the work of TFORD to date&nbsp; NEW!! (17 May 2020, Pune Times, Times of India) Remdesivir vs Favipiravir &amp; other repurpose drugs for COVID-19: Link (14 May 2020, ToI) Bengal government recommends rheumatoid arthritis drug to fight &hellip; <a href=\"https:\/\/nclinnovations.org\/covid19\/in-the-news\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">In the News<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template\/page\/fullwidth.php","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/pages\/234"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/comments?post=234"}],"version-history":[{"count":10,"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/pages\/234\/revisions"}],"predecessor-version":[{"id":293,"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/pages\/234\/revisions\/293"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/media?parent=234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}